Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Nov 20, 2015 Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma
Nov 6, 2015 Celldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 5, 2015 Form 10-Q View HTML View PDF 330.4 KB Add to Briefcase
Feb 24, 2015 Form 10-K View HTML View PDF 1.1 MB Add to Briefcase
Add to Briefcase = add file to Briefcase